GlassScriptPhysician profile
Henry D Crowley
NPI 1215937941
$5,429.35
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $83.05 · 2022: $728 · 2023: $2,256 · 2024: $2,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,333 · Education: $24.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,333.26 |
| Education | $24.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,878.60 | 2022-2024 | Linzess, Skyrizi, Viberzi |
| Celgene Corporation | $535.02 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $470.71 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $411.16 | 2022-2024 | Entyvio |
| Ardelyx, INC. | $376.63 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.18 | 2022-2024 | Xifaxan, Trulance |
| Collegium Pharmaceutical, INC. | $304.36 | 2019-2020 | |
| Genzyme Corporation | $263.45 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $155.95 | 2022-2024 | Rebyota |
| Idorsia Pharmaceuticals US INC | $152.67 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $97.89 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $95.72 | 2024 | Dupixent |
| Lilly USA, LLC | $77.31 | 2024 | Omvoh |
| Gilead Sciences, INC. | $54.64 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $43.95 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $38.45 | 2023-2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $28.89 | 2024 | |
| Celltrion USA INC. | $24.73 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $23.15 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2024 | Cyltezo |
| Amgen INC. | $18.09 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.